BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26241262)

  • 1. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
    Mainiero AD; Rouse DJ; Lopes V; Hughes BL
    Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO; Stamilio DM; Macones GA; Polsky D
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
    Combs CA; Garite TJ; Maurel K; Abril D; Das A; Clewell W; Heyborne K; How H; Huang W; Lewis D; Lu G; Miller H; Nageotte M; Porreco R; Sheikh A; Tran L;
    Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
    Awwad J; Usta IM; Ghazeeri G; Yacoub N; Succar J; Hayek S; Saasouh W; Nassar AH
    BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy.
    Waters TP; Schultz BAH; Mercer BM; Catalano PM
    Obstet Gynecol; 2009 Jul; 114(1):45-49. PubMed ID: 19546757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
    Stetson B; Hibbard JU; Wilkins I; Leftwich H
    Obstet Gynecol; 2016 Nov; 128(5):983-988. PubMed ID: 27741201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
    Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
    Saghafi N; Khadem N; Mohajeri T; Shakeri MT
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rates of abnormal glucose challenge tests and gestational diabetes in women receiving 17α-hydroxyprogesterone caproate.
    Wolfe K; Dearmond C; How H; Henderson ZT; Sibai B
    Am J Perinatol; 2011 Dec; 28(10):741-6. PubMed ID: 21660898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM; Lewis DF
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
    Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
    Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Merlob P; Stahl B; Klinger G
    Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
    Suresh S; Freedman A; Adams M; Hirsch E; Ernst LM
    Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial.
    Facchinetti F; Vergani P; Di Tommaso M; Marozio L; Acaia B; Vicini R; Pignatti L; Locatelli A; Spitaleri M; Benedetto C; Zaina B; DʼAmico R
    Obstet Gynecol; 2017 Jul; 130(1):64-70. PubMed ID: 28594783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
    Co AL; Walker HC; Hade EM; Iams JD
    Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.